Real-world hemoglobin (Hb) outcomes of patients with lower-risk myelodysplastic syndromes (LR-MDS) receiving first-line (1L) luspatercept or 1L erythropoiesis-stimulating agents (ESAs) in the US
Real-world study shows improved hemoglobin outcomes in patients with anemia from LR-MDS treated with luspatercept, suggesting benefits over ESA therapy.
Key Points
Assess hemoglobin outcomes in patients with lower-risk myelodysplastic syndromes receiving first-line luspatercept or erythropoiesis-stimulating agents.
Retrospective review of medical records from patients with low-risk MDS
Data collection period between November 2024 and March 2025
Analysis of hemoglobin response following treatment initiation
69.6% of patients on luspatercept achieved hemoglobin ≥10 g/dL compared to 58.0% on ESA
Median time to achieve hemoglobin ≥10 g/dL was 2.3 months for luspatercept vs 5.3 months for ESA
Adjusted hazard ratio for achieving hemoglobin ≥10 g/dL was 1.44 for luspatercept compared to ESA